A Study of the Efficacy and Safety of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis

Inclusion Criteria:

Ability to provide written informed consent and to be compliant with the schedule of protocol assessments
Relapsing-remitting multiple sclerosis (MS)
Ages 18-55 years inclusive
For sexually active female and male participants of reproductive potential, use of reliable means of contraception

Exclusion Criteria:

Secondary or primary progressive multiple sclerosis at screening
Incompatibility with MRI
Contra-indications to or intolerance of oral or IV corticosteroids
Known presence of other neurologic disorders
Pregnancy or lactation
Lack of peripheral venous access
History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies
Significant, uncontrolled disease, such as cardiovascular, pulmonary, renal, hepatic, endocrine or gastrointestinal
Congestive heart failure
Known active bacterial, viral, fungal, mycobacterial infection or other infection or any major episode of infection requiring hospitalization or treatment with IV antibiotics within 4 weeks prior to screening or oral antibiotics within 2 weeks prior to screening
History or known presence of recurrent or chronic infection
History of cancer, including solid tumors and hematological malignancies (except basal cell, in situ squamous cell carcinomas of the skin, and in situ carcinoma of the cervix of the uterus that have been excised and resolved)
History of alcohol or drug abuse within 24 weeks prior to randomization
History of or currently active primary or secondary immunodeficiency
History of coagulation disorders
Treatment with any investigational agent within 4 weeks of screening
Receipt of a live vaccine within 6 weeks prior to randomization
Incompatibility with Avonex use
Previous treatment with rituximab
Previous treatment with lymphocyte-depleting therapies except mitoxantrone
Treatment with lymphocyte trafficking blockers within 24 weeks prior to randomization
Treatment with beta interferons, glatiramer acetate, IV immunoglobulin, plasmapheresis, or immunosuppressive therapies within 12 weeks prior to randomization
Systemic corticosteroid therapy within 4 weeks prior to randomization